Intravitreal Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion in Chinese Patients.

眼科学报 Pub Date : 2015-06-11 DOI:10.3969/J.ISSN.1000-4432.2015.02.004

Jiakui Wang, Tzu-Lun Huang, P. Su, P. Chang, Ying-Yu Tseng

{"title":"Intravitreal Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion in Chinese Patients.","authors":"Jiakui Wang, Tzu-Lun Huang, P. Su, P. Chang, Ying-Yu Tseng","doi":"10.3969/J.ISSN.1000-4432.2015.02.004","DOIUrl":null,"url":null,"abstract":"PURPOSE\nTo investigate the short-term efficacy and safety of intravitreal aflibercept in a case series of patients from Taiwan, China, with macular edema secondary to branch retinal vein occlusion (BRVO).\n\n\nMETHODS\nA total of 32 patients with macular edema associated with BRVO, without prior macular laser or other intervention, were enrolled consecutively from September 2013 to February 2015. The cases received single 2 mg injections of intravitreal aflibercept. Primary outcome measures included changes in central foveal thickness (CFT; 1 mm increments by spectral-domain optic coherence tomography) and best corrected visual acuity (BCVA), determined at 1, 2, and 3 months after the injection. Complications after injections were recorded. The changes in CFT and BCVA were compared with Wilcoxon sign-rank tests.\n\n\nRESULTS\nThe CFT was significantly reduced and the BCVA was significantly improved at 1, 2, and 3 months after injection (all P < 0.05). Tomography findings revealed no recurrence within 3 months. No systemic thromboembolic events, elevated intraocular pressure, retinal detachment, or infectious endophthalmitis occurred following injection.\n\n\nCONCLUSION\nSingle intravitreal aflibercept may be useful in treating macular edema associated with BRVO within 3 months. No adverse systemic or ocular effects were found in this case series.","PeriodicalId":12096,"journal":{"name":"眼科学报","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"眼科学报","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3969/J.ISSN.1000-4432.2015.02.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 7

Abstract

PURPOSE To investigate the short-term efficacy and safety of intravitreal aflibercept in a case series of patients from Taiwan, China, with macular edema secondary to branch retinal vein occlusion (BRVO). METHODS A total of 32 patients with macular edema associated with BRVO, without prior macular laser or other intervention, were enrolled consecutively from September 2013 to February 2015. The cases received single 2 mg injections of intravitreal aflibercept. Primary outcome measures included changes in central foveal thickness (CFT; 1 mm increments by spectral-domain optic coherence tomography) and best corrected visual acuity (BCVA), determined at 1, 2, and 3 months after the injection. Complications after injections were recorded. The changes in CFT and BCVA were compared with Wilcoxon sign-rank tests. RESULTS The CFT was significantly reduced and the BCVA was significantly improved at 1, 2, and 3 months after injection (all P < 0.05). Tomography findings revealed no recurrence within 3 months. No systemic thromboembolic events, elevated intraocular pressure, retinal detachment, or infectious endophthalmitis occurred following injection. CONCLUSION Single intravitreal aflibercept may be useful in treating macular edema associated with BRVO within 3 months. No adverse systemic or ocular effects were found in this case series.

查看原文本刊更多论文

玻璃体内注射阿非利塞治疗中国视网膜分支静脉阻塞继发黄斑水肿。

目的观察玻璃体内注射阿布西普治疗中国台湾继发视网膜分支静脉阻塞(BRVO)黄斑水肿的近期疗效和安全性。方法于2013年9月至2015年2月连续选取32例黄斑水肿合并BRVO患者，均未进行黄斑激光或其他干预。所有病例均接受玻璃体内单次注射2 mg。主要预后指标包括中央中央凹厚度(CFT;在注射后1、2和3个月测定最佳矫正视力(BCVA)。记录注射后并发症。CFT和BCVA的变化比较采用Wilcoxon符号秩检验。结果注射后1、2、3个月CFT明显降低，BCVA明显改善(均P < 0.05)。3个月内未见复发。注射后未发生全身性血栓栓塞事件、眼压升高、视网膜脱离或感染性眼内炎。结论单次玻璃体内注射阿布利塞可有效治疗BRVO合并黄斑水肿3个月。在本病例系列中未发现不良的全身或眼部影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

眼科学报

自引率

0.00%

发文量

1312

期刊介绍： Eye science was founded in 1985. It is a national medical journal supervised by the Ministry of Education of the People's Republic of China, sponsored by Sun Yat-sen University, and hosted by Sun Yat-sen University Zhongshan Eye Center (in October 2020, it was changed from a quarterly to a monthly, with the publication number: ISSN: 1000-4432; CN: 44-1119/R). It is edited by Ge Jian, former dean of Sun Yat-sen University Zhongshan Eye Center, Liu Yizhi, director and dean of Sun Yat-sen University Zhongshan Eye Center, and Lin Haotian, deputy director of Sun Yat-sen University Zhongshan Eye Center, as executive editor. It mainly reports on new developments and trends in the field of ophthalmology at home and abroad, focusing on basic research in ophthalmology, clinical experience, and theoretical knowledge and technical operations related to epidemiology. It has been included in important databases at home and abroad, such as Chemical Abstract (CA), China Journal Full-text Database (CNKI), China Core Journals (Selection) Database (Wanfang), and Chinese Science and Technology Journal Database (VIP).